A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I 131 1095 Radiotherapy in combination with enzalutamide in metastatic castration resistant prOstate cancer (mCRPC) patients Who are 18F DCFPyL prostate specific membrane antigen (PSMA) avid, chemotherapy naïve, and progressed on abiraterone (ARROW)

Gender
Any

Age Group
Any

At a Glance

IRB#IRB19-0254

Lead PhysicianRussell Szmulewitz

Collaborator(s)N/A

EligibilityNot Recruiting